Brokerages Set Selecta Biosciences, Inc. (SELB) Price Target at $27.75
Selecta Biosciences, Inc. (NASDAQ:SELB) has earned an average rating of “Buy” from the six analysts that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have issued a buy recommendation on the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $27.75.
A number of research firms have weighed in on SELB. Zacks Investment Research cut shares of Selecta Biosciences from a “hold” rating to a “sell” rating in a research report on Wednesday, August 16th. Canaccord Genuity set a $25.00 price objective on shares of Selecta Biosciences and gave the company a “buy” rating in a research report on Friday, August 11th. Finally, ValuEngine raised shares of Selecta Biosciences from a “sell” rating to a “hold” rating in a research report on Friday, June 30th.
In other news, Director Timothy A. Springer acquired 338,791 shares of the firm’s stock in a transaction on Tuesday, June 27th. The stock was bought at an average cost of $17.71 per share, with a total value of $5,999,988.61. Following the transaction, the director now directly owns 355,413 shares in the company, valued at approximately $6,294,364.23. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Peter Keller sold 4,595 shares of the company’s stock in a transaction dated Tuesday, June 27th. The shares were sold at an average price of $19.30, for a total transaction of $88,683.50. Following the completion of the transaction, the insider now directly owns 5,000 shares of the company’s stock, valued at $96,500. The disclosure for this sale can be found here. Over the last three months, insiders sold 55,024 shares of company stock valued at $1,030,364.
Institutional investors have recently bought and sold shares of the stock. Wasatch Advisors Inc. boosted its position in Selecta Biosciences by 66.5% in the second quarter. Wasatch Advisors Inc. now owns 124,392 shares of the company’s stock worth $2,470,000 after buying an additional 49,690 shares during the last quarter. California State Teachers Retirement System boosted its position in Selecta Biosciences by 98.1% in the second quarter. California State Teachers Retirement System now owns 20,800 shares of the company’s stock worth $413,000 after buying an additional 10,300 shares during the last quarter. The Manufacturers Life Insurance Company boosted its position in Selecta Biosciences by 827.0% in the second quarter. The Manufacturers Life Insurance Company now owns 11,254 shares of the company’s stock worth $224,000 after buying an additional 10,040 shares during the last quarter. State Street Corp boosted its position in Selecta Biosciences by 118.5% in the second quarter. State Street Corp now owns 152,430 shares of the company’s stock worth $3,027,000 after buying an additional 82,665 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in Selecta Biosciences by 175.5% in the second quarter. Vanguard Group Inc. now owns 217,634 shares of the company’s stock worth $4,322,000 after buying an additional 138,646 shares during the last quarter. 48.09% of the stock is owned by institutional investors.
Selecta Biosciences (NASDAQ:SELB) traded up 1.04% on Friday, reaching $15.61. The company had a trading volume of 65,281 shares. The stock’s 50-day moving average price is $17.69 and its 200 day moving average price is $15.08. Selecta Biosciences has a 52-week low of $10.27 and a 52-week high of $28.00.
Selecta Biosciences (NASDAQ:SELB) last announced its quarterly earnings results on Friday, August 11th. The company reported ($0.85) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.86) by $0.01. Selecta Biosciences had a negative return on equity of 88.31% and a negative net margin of 1,277.76%. The firm had revenue of $0.03 million during the quarter. Equities research analysts expect that Selecta Biosciences will post ($3.17) EPS for the current year.
Selecta Biosciences Company Profile
Selecta Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases.
Receive News & Ratings for Selecta Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.